Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial

被引：0
|
作者：
Qiuling Zhao
Ruixiang Xie
Wanfu Zhong
Wenbin Liu
Ting Chen
Xiuliang Qiu
Lin Yang
机构：
[1] Clinical Oncology School of Fujian Medical University,Department of Pharmacy
[2] Fujian Cancer Hospital,Department of Pharmacy
[3] Fujian University of Traditional Chinese Medicine,undefined
来源：
Cost Effectiveness and Resource Allocation | / 21卷
关键词：
Durvalumab; PD-L1; Biliary tract cancer; First-line treatment; Cost-effectiveness analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial
    Zhao, Qiuling
    Xie, Ruixiang
    Zhong, Wanfu
    Liu, Wenbin
    Chen, Ting
    Qiu, Xiuliang
    Yang, Lin
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [2] Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer
    Ye, Zhuo-miao
    Xu, Zhe
    Li, Huan
    Li, Qian
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [3] Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer
    Oh, Do-Youn
    He, Aiwu Ruth
    Qin, Shukui
    Chen, Li-Tzong
    Okusaka, Takuji
    Vogel, Arndt
    Kim, Jin Won
    Suksombooncharoen, Thatthan
    Lee, Myung Ah
    Kitano, Masayuki
    Burris, Howard
    Bouattour, Mohamed
    Tanasanvimon, Suebpong
    McNamara, Mairead G.
    Zaucha, Renata
    Avallone, Antonio
    Tan, Benjamin
    Cundom, Juan
    Lee, Choong-kun
    Takahashi, Hidenori
    Ikeda, Masafumi
    Chen, Jen-Shi
    Wang, Julie
    Makowsky, Mallory
    Rokutanda, Nana
    Zotkiewicz, Magdalena
    Kurland, John F.
    Cohen, Gordon
    Valle, Juan W.
    FUTURE ONCOLOGY, 2023, 19 (34) : 2277 - 2289
  • [4] Durvalumab Plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (TOPAZ-1)
    Choe, Jung Wan
    KOREAN JOURNAL OF GASTROENTEROLOGY, 2023, 82 (02): : 105 - 106
  • [5] Cost-effectiveness analysis of pembrolizumab in combination with chemotherapy compared with chemotherapy alone as first-line treatment for patients with advanced biliary tract cancer in China
    Zheng, Zhiwei
    Fang, Ling
    Cai, Hongfu
    BMC CANCER, 2023, 23 (01)
  • [6] Cost-effectiveness analysis of pembrolizumab in combination with chemotherapy compared with chemotherapy alone as first-line treatment for patients with advanced biliary tract cancer in China
    Zhiwei Zheng
    Ling Fang
    Hongfu Cai
    BMC Cancer, 23
  • [7] Comparative Cost-Effectiveness of Gemcitabine and Cisplatin in Combination with S-1, Durvalumab, or Pembrolizumab as First-Line Triple Treatment for Advanced Biliary Tract Cancer
    Kashiwa, Munenobu
    Maeda, Hiroyuki
    JOURNAL OF GASTROINTESTINAL CANCER, 2024, 55 (04) : 1569 - 1580
  • [8] Cost-effectiveness of pembrolizumab plus chemotherapy vs. chemotherapy as first-line treatment for advanced biliary tract cancer in China and the US
    Luo, Xianmei
    Cai, Tingting
    Wu, Jinyan
    Li, Xingyu
    Wang, Xiaofan
    Ma, Haiying
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [9] Cost-effectiveness analysis of immune checkpoint inhibitors as first-line therapy in advanced biliary tract cancer
    Liu, Ruizhe
    Zhao, Yijia
    Shi, Fenghao
    Zhu, Jianhong
    Wu, Junyan
    Huang, Min
    Qiu, Kaifeng
    IMMUNOTHERAPY, 2024, 16 (10) : 669 - 678
  • [10] Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis
    Zhu, Youwen
    Liu, Kun
    Ding, Dong
    Zhou, Yangying
    Peng, Libo
    ADVANCES IN THERAPY, 2022, 39 (06) : 2614 - 2629
12345